CLARITY IN BIOLOGICAL UNCERTAINTY
Building the human reference standard for
drug development
Modern drug discovery generates biological signals at unprecedented scale. Yet the most consequential safety questions still only become clear in humans.
We think that's too late.
Scroll to learn
OUR MISSION
At Vistrix, we bring greater human clarity to drug development decisions before clinical testing.
Preclinical evidence was never designed to function as a unified human reference framework. As a result, critical development decisions are often made across fragmented biological signals with no common human reference point.
That is not simply a data problem. It is an infrastructure problem. Vistrix is building the infrastructure that drug development has been missing.
THE PROBLEM
Critical development decisions are being made across fragmented biological signals with no common human reference point. Some of the most consequential safety questions in drug development only become clear in humans — and by then, it is too late.
HOW IT WORKS
A structured human
risk assessment.
Delivered before clinical commitment is made.
WHY NOW
Three things are true
simultaneously.
Human cellular systems have matured dramatically. The cost of late-stage safety failures has never been more visible. And regulatory agencies are actively creating space for human-relevant preclinical evidence. Together, these shifts are creating urgency for a stronger human reference standard.
Mature human cellular systems
The biological tools required to generate meaningful human-relevant safety signals now exist at the quality and scale needed for drug development workflows.
Visible cost of late-stage failure
The industry's exposure to late-stage safety failures has never been higher or more visible. Earlier clarity is not just scientifically sound — it is economically essential.
Regulatory momentum
Agencies are actively creating space for human-relevant preclinical evidence, rewarding development teams who can present a rigorous human reference framework.
WHO WE WORK WITH
Designed for high-stakes preclinical decisions.
Vistrix is designed for drug development teams making high-stakes preclinical decisions under biological uncertainty. Our initial focus is small molecule programs at the hit-to-lead and lead optimisation stages, where earlier human clarity can still meaningfully change the trajectory of a program before IND-enabling commitment.
Biotech companies
Early-stage programs where human safety clarity before IND can de-risk program investment and support better candidate selection.
Translational research groups
Academic and institutional teams bridging discovery and development who need structured human evidence to advance their programs.
Drug discovery teams
Internal teams at pharmaceutical organisations who require human-relevant safety evidence as part of their preclinical decision framework.
Dr Crystal Chia
FOUNDER & CEO
Cambridge
Wellcome Sanger
Cancer Research UK
Duke-NUS
A*STAR
Engine Biosciences
FOUNDED BY
Dr Crystal Chia is a biotech founder and scientist with deep expertise across stem cell biology, human genetics, genome engineering, and oncology-focused drug discovery.
Vistrix was founded from her direct experience at the intersection of human biology and preclinical decision-making — and the gap she observed between the two.
Built from direct experience at the intersection of human biology and preclinical decision-making.
GET IN TOUCH
Ready to bring human clarity to your program?
We work with biotech companies, translational research groups, and drug discovery teams at the hit-to-lead and lead optimisation stages.
